NCT06388759View on ClinicalTrials.gov

TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

August 12, 2025

Study Completion Date

August 12, 2025

Conditions
Myelofibrosis
Interventions
DRUG

TQ05105 Tablets

TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 （JAK2） Inhibitor

Trial Locations (6)

130021

The First Hospital of Jilin University, Changchun

200233

Shanghai Sixth People's Hospital, Shanghai

221000

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

230001

Anhui Provincial Hospital, Hefei

241001

The First Affiliated Hospital of Wannan Medical College, Wuhu

430071

Union Hospital Tongji College Huazhong University of Science And Technology, Wuhan

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY